About Magnus Medical

We are a neurotechnology company backed by recognized groundbreaking science. We pioneered the first and only FDA-cleared, noninvasive brain stimulation therapy using functional connectivity targeting to bring lasting remission to people living with Major Depressive Disorder (MDD)

We’re leading a new era in brain health

Our mission

To restore brain health by making proven, rapid-remission treatment accessible for the millions of people living with depression.

We exist to give people a real way forward. With empathy, precision, and proven results, we’re rewriting the story of brain health treatments—for patients, clinicians, and the entire system around them.

Our vision

To redefine what’s possible in brain health by delivering precise, rapid-acting treatments that eliminate disease and give people back their ability to think, feel, and thrive.

We know that brain health is the starting point and with SAINT® Depression Therapy, the route to recovery is finally clear.

Our story

Originally developed at Stanford University, SAINT is now licensed exclusively to Magnus Medical to turn a scientific revolution in brain health into real-life impact, offering new hope and healing for millions of people living with brain conditions.

2017
SAINT developed

Psychiatrists and neuroscientists at Stanford’s Brain Stimulation Lab combined targeted therapy with a highly accelerated treatment protocol to stimulate neural networks and rebuild healthy connectivity.

2020
Magnus Medical founded

Stanford licensed SAINT exclusively to Magnus Medical for further development and commercialization of the treatment, expanding access for people in need outside of a clinical research environment.

2021
Landmark clinical trial

Published in the American Journal of Psychiatry, the results of this landmark double-blind randomized controlled trial were groundbreaking and pivotal in achieving FDA clearance for SAINT.

2023
New Technology Add-On Payment

SAINT was granted the first-ever NTAP approval for interventional psychiatry, enabling additional Medicare reimbursement for hospitals.

2022
FDA-clearance

SAINT received 510(k) clearance from the U.S. FDA for the treatment of major depressive disorder (MDD) in adults who have failed to achieve satisfactory improvement from prior antidepressant medications.

2021
Breakthrough designation

The U.S. FDA granted Breakthrough Device Designation to SAINT. This program expedites access to technologies offering more effective treatment for serious conditions.

2024
SAINT commercialization

The official shift of SAINT from a research breakthrough to a commercially available clinical treatment began with early adopters of the technology across the U.S.

2024
New Tech Ambulatory Payment Classification

SAINT was granted NTAPC status for outpatient care, securing a dedicated Medicare payment pathway to support patient access to high-efficacy care.

2025
Series B

This round of funding marked a pivotal step toward scaling SAINT and expanding access to rapid, precision treatment for depression.

Leadership

Our executive team is committed to defining the future of brain health, guided by shared values and a strategic vision to eradicate suffering from brain conditions through groundbreaking science.

image
Christian Gormsen
Chief Executive Officer

Christian Gormsen brings over two decades of operational leadership experience across diverse continents and industries. Prior to Magnus, he was President and CEO of Eargo, where he orchestrated the company’s rise to surpass a +$100 million run rate by 2021, secured over $500 million in capital, and led the successful 2020 IPO. He also held a strategic Senior Vice President role at GN Group, overseeing operations across 14 countries, and was Chief Operating Officer of Sterling Air. He holds a Master of Science in Finance and Accounting from the Copenhagen Business School.

LinkedIn
image
Brandon Bentzley, MD, PhD
Co-Founder & Chief Science Officer

Dr. Brandon Bentzley, is co-founder and Chief Scientific Officer of Magnus Medical. His interest in neuroscience led him to the Medical University of South Carolina (MUSC), the birthplace of clinical transcranial magnetic stimulation, where he completed his MD and PhD. He completed his residency and postdoctoral training at Stanford University, focusing on the development of SAINT technology. With over 15 years of experience in developing advanced automated systems, he has published in high-impact peer-reviewed journals, his clinical focus being in treatment-resistant depression and substance abuse disorders.

LinkedIn
image
Achal Singh Achrol, MD, FAANS
Chief Medical Officer

Dr. Achal Singh Achrol is a neurosurgeon, executive leader, and entrepreneur with 20 years of experience spanning academia, medtech, and biotech. He began his career as neurosurgery faculty with a focus on clinical trials and translational neuroscience research. As a Principal Investigator, he has led clinical trials for noninvasive and minimally-invasive neurosurgical technologies in neuro-oncology, traumatic brain injury, stroke, and neurodegenerative and neuropsychiatric diseases.

LinkedIn
image
Vikram Lamba
Chief Financial Officer

Vikram Lamba brings over three decades of global healthcare experience with both large pharmaceutical companies and startup entities. He is responsible for operations and business development. His career includes serving as CFO and head of business development at ImmPACT Bio USA and founding CFO at Civica, Inc. Earlier in his career, he held executive roles in M&A and as a divisional CFO at Bayer AG for over eight years. He received his MBA from the Asian Institute of Management after earning his undergraduate degree in mechanical engineering.

LinkedIn
image
Romain Moreau-Gobard
Senior Vice President of Technology

Romain Moreau-Gobard has been integral in building the company’s product and business strategy from inception. He has a distinguished career developing advanced medical imaging software and excels at overseeing the FDA 510(k) pathway to clearance. During his tenure at Magnus, the company achieved FDA clearance and Medicare reimbursements. Previously, he was Director of Engineering at HeartFlow for almost ten years, where he architected a novel software as a medical device (SAMD) and delivered the company’s first FDA-cleared product. He holds 15 US and international patents and a master’s degree in Artificial Intelligence.

LinkedIn
image
Huyen Duong
Vice President of Clinical, Quality and Regulatory

Huyen Duong brings over 25 years of experience in leading clinical, quality, and regulatory affairs organizations at established medical technology companies and early startups. Previously, she was VP of Regulatory Affairs and Quality Assurance at Nesos Corporation, where she defined regulatory and clinical strategies to support global commercialization of their non-invasive neuromodulation platform. Prior to that, as Senior Director at Nevro Corporation, she supported pre- and post-market regulatory activities and managed over 20 clinical investigations. She has also held senior management positions in regulatory affairs at Boston Neuromodulation and Bausch and Lomb.

LinkedIn
image
Matt Wallace
Vice President of Sales

Matthew Wallace leads end-to-end customer engagement across the US markets. Since joining Magnus, he has built the commercial team, managed the healthcare system business, and developed the go-to-market strategy for the SAINT launch in outpatient settings. Prior to Magnus, he was the Vice President of Sales for the Americas and LATAM regions at Insightec. He has held numerous leadership roles launching truly disruptive innovations at medical device companies including Auris Health, iRhythm, Stereotaxis, and Intuitive Surgical.

LinkedIn
image
Tricia Burchell
Head of People Operations

Tricia is a seasoned People Operations leader with over 30 years of experience across multiple industries, specializing in high-growth, globally scaling technology companies. Her career began at NASA’s Life Sciences Team, where she collaborated with scientists and engineers to support astronaut life on the Space Station. Following this, she pivoted to the startup world, contributing to two successful IPOs: first with Cloudera, where she scaled the company from 75 to over 1,300 employees and opened entities in 28 countries, and most recently at Eargo as SVP People Strategy.

LinkedIn
Investors
dolby family ventures logo
jazz venture partners
khosla ventures logo
maj invest logo
mubadala logo
red tree venture capital logo
dolby family ventures logo
jazz venture partners
khosla ventures logo
maj invest logo
mubadala logo
red tree venture capital logo
dolby family ventures logo
jazz venture partners
khosla ventures logo
maj invest logo
mubadala logo
red tree venture capital logo
dolby family ventures logo
jazz venture partners
khosla ventures logo
maj invest logo
mubadala logo
red tree venture capital logo

Work with purpose

Join our passionate team advancing brain health science with urgency and empathy.

Explore careers